Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18602945 | 1.00 | PGR (0.31) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL19696782 | 0.84 | FDPS (0.33) | FDPS | |
| SCHEMBL2567591 | 0.79 | FDPS (0.36) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL2564580 | 0.79 | PGR (0.30) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL23950126 | 0.75 | PGR (0.31) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL13266482 | 0.75 | FDPS (0.31) | FDPSTSHR | |
| SCHEMBL10284280 | 0.73 | FDPS (0.33) | FDPS | |
| SCHEMBL25806850 | 0.73 | FDPS (0.33) | FDPS | |
| SCHEMBL13417347 | 0.73 | FDPS (0.33) | FDPS | |
| SCHEMBL13284221 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844040-A1 | TRANSPARENT ELECTRODE, ELECTRONIC DEVICE, AND TRANSPARENT ELECTRODE MANUFACTURING METHOD | Konica Minolta, Inc. (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | PGR 1783/4885ADRA2A 114/4885ADRA2B 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.